| Autor: |
Hinger D, Navarro F, Käch A, Thomann JS, Mittler F, Couffin AC, Maake C |
| Rok vydání: |
2016 |
| Zdroj: |
J Nanobiotechnology |
| DOI: |
10.1186/s12951-016-0221-x |
| Popis: |
BACKGROUND: Photosensitizers are used in photodynamic therapy (PDT) to destruct tumor cells however their limited solubility and specificity hampers routine use which may be overcome by encapsulation. Several promising novel nanoparticulate drug carriers including liposomes polymeric nanoparticles metallic nanoparticles and lipid nanocomposites have been developed. However many of them contain components that would not meet safety standards of regulatory bodies and due to difficulties of the manufacturing processes reproducibility and scale up procedures these drugs may eventually not reach the clinics. Recently we have designed a novel lipid nanostructured carrier namely Lipidots consisting of nontoxic and FDA approved ingredients as promising vehicle for the approved photosensitizer m tetrahydroxyphenylchlorin (mTHPC). RESULTS: In this study we tested Lipidots of two different sizes (50 and 120 nm) and assessed their photodynamic potential in 3 dimensional multicellular cancer spheroids. Microscopically the intracellular accumulation kinetics of mTHPC were retarded after encapsulation. However after activation mTHPC entrapped into 50 nm particles destroyed cancer spheroids as efficiently as the free drug. Cell death and gene expression studies provide evidence that encapsulation may lead to different cell killing modes in PDT. CONCLUSIONS: Since ATP viability assays showed that the carriers were nontoxic and that encapsulation reduced dark toxicity of mTHPC we conclude that our 50 nm photosensitizer carriers may be beneficial for clinical PDT applications. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
